A number of other brokerages also recently issued reports on BTG. Numis Securities Ltd reiterated a hold rating and issued a GBX 737 ($9.12) price target on shares of BTG plc in a report on Thursday, July 14th. Stifel Nicolaus downgraded shares of BTG plc to a hold rating in a report on Thursday, July 14th. JPMorgan Chase & Co. raised their target price on shares of BTG plc from GBX 790 ($9.78) to GBX 830 ($10.27) and gave the company a neutral rating in a report on Friday, October 7th. Finally, Jefferies Group raised their target price on shares of BTG plc from GBX 840 ($10.40) to GBX 860 ($10.64) and gave the company a buy rating in a report on Wednesday, June 29th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of GBX 799.57 ($9.90).
BTG plc (LON:BTG) opened at 695.50 on Friday. The stock has a 50 day moving average of GBX 635.42 and a 200 day moving average of GBX 642.74. The firm’s market capitalization is GBX 2.66 billion. BTG plc has a one year low of GBX 504.00 and a one year high of GBX 739.50.
In other news, insider Soderstrom,Rolf sold 74,327 shares of BTG plc stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of GBX 676 ($8.37), for a total transaction of £502,450.52 ($621,844.70).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.